Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.
2.

Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis.

Suthar AB, Vitoria MA, Nagata JM, Anglaret X, Mbori-Ngacha D, Sued O, Kaplan JE, Doherty MC.

Lancet HIV. 2015 Apr;2(4):e137-50. doi: 10.1016/S2352-3018(15)00005-3. Epub 2015 Mar 3. Review.

PMID:
26424674
3.

Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection.

Gill CJ, Sabin LL, Tham J, Hamer DH.

Bull World Health Organ. 2004 Apr;82(4):290-7. Review.

4.

Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries.

Zachariah R, Harries AD, Luo C, Bachman G, Graham SM.

Lancet Infect Dis. 2007 Oct;7(10):686-93. Review.

PMID:
17897611
5.

Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries.

Zachariah R, Massaquoi M.

Trop Doct. 2006 Apr;36(2):79-82. Review.

PMID:
16611438
6.

[Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].

Pozio E.

Parassitologia. 2004 Jun;46(1-2):89-93. Review. Italian.

PMID:
15305694
7.

Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in infants and children born to women infected with human immunodeficiency virus.

Wilfert CM, Masur H, Gross PA, Kaplan JE, Holmes KK, Phair JP, Simonds RJ.

Clin Infect Dis. 1995 Aug;21 Suppl 1:S132-3. Review. No abstract available.

PMID:
8547506
8.

Clinical aspects of Pneumocystis carinii pneumonia in HIV-infected patients: 1997.

Miller R.

FEMS Immunol Med Microbiol. 1998 Sep;22(1-2):103-5. Review.

9.

Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in adults and adolescents infected with human immunodeficiency virus.

Phair JP, Masur H, Gross PA, Holmes KK, Kaplan JE.

Clin Infect Dis. 1995 Aug;21 Suppl 1:S128-9. Review. No abstract available.

PMID:
8547504
10.

[Prevention of opportunistic infections in HIV-infected adults].

Furrer H, Malinverni R.

Ther Umsch. 1998 May;55(5):302-9. Review. German.

PMID:
9643128
11.

Pneumocystis carinii infection: current treatment and prevention.

Miller RF, Le Noury J, Corbett EL, Felton JM, De Cock KM.

J Antimicrob Chemother. 1996 May;37 Suppl B:33-53. Review.

PMID:
8818828
12.

Primary and secondary prophylaxis for Pneumocystis carinii related complications in HIV patients.

Held M, Goebel FD.

Eur Respir J. 1996 May;9(5):868-71. Review. No abstract available.

13.

Global strategies to prevent bacterial pneumonia in adults with HIV disease.

Feikin DR, Feldman C, Schuchat A, Janoff EN.

Lancet Infect Dis. 2004 Jul;4(7):445-55. Review.

PMID:
15219555
14.

The expanding role of co-trimoxazole in developing countries.

Church JA, Fitzgerald F, Walker AS, Gibb DM, Prendergast AJ.

Lancet Infect Dis. 2015 Mar;15(3):327-39. doi: 10.1016/S1473-3099(14)71011-4. Epub 2015 Jan 21. Review. Erratum in: Lancet Infect Dis. 2015 Mar;15(3):263.

PMID:
25618179
15.

Co-trimoxazole prophylaxis in HIV: the evidence.

Young T, Oliphant CE, Araoyinbo I, Volmink J.

S Afr Med J. 2008 Apr;98(4):258-9. Review. No abstract available.

PMID:
18637628
16.

Limitations of and indications for the use of co-trimoxazole.

Brumfitt W, Hamilton-Miller JM.

J Chemother. 1994 Feb;6(1):3-11. Review.

PMID:
8071675
17.

Therapeutic progress. IV: Treatment and prophylaxis of Pneumocystis carinii infection.

Jolley AE, Hastings JG.

J Clin Pharm Ther. 1995 Jun;20(3):121-30. Review.

PMID:
7593374
18.

Iron status and the outcome of HIV infection: an overview.

Gordeuk VR, Delanghe JR, Langlois MR, Boelaert JR.

J Clin Virol. 2001 Feb;20(3):111-5. Review.

PMID:
11166657
19.

Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis.

van der Ven AJ, Vree TB, Koopmans PP, van der Meer JW.

J Antimicrob Chemother. 1996 May;37 Suppl B:55-60. Review.

PMID:
8818829
20.

Supplemental Content

Support Center